1 / 7

Chapter Nine Venous Disease Coalition

Chapter Nine Venous Disease Coalition. New Therapies for VTE. VTE T oolkit. Iliofemoral DVT has more serious long-term consequences than infra-inguinal DVT After 5 years: - 95% develop chronic venous insufficiency - nearly ½ have venous claudication - 15% develop venous ulcers

angus
Download Presentation

Chapter Nine Venous Disease Coalition

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter Nine Venous Disease Coalition New Therapies for VTE VTE Toolkit

  2. Iliofemoral DVT has more serious long-term consequences than infra-inguinal DVT • After 5 years: • - 95% develop chronic venous insufficiency • - nearly ½ have venous claudication • - 15% develop venous ulcers • - substantially reduced Quality of Life Iliofemoral DVT VTE Toolkit

  3. Potential Benefits of Clot Removal: • More rapid relief of obstruction • Preservation of valve function • Reduction in clot recurrence • Reduction in post-thrombotic morbidity Iliofemoral DVT VTE Toolkit

  4. Catheter-Directed Thrombus Reduction: • Successful thrombolysis • - more rapid return to function • - reduced chronic post-thrombotic symptoms • - improved quality of life • Bleeding  • - Major bleeding <5% • - Intracranial bleeding <1% • Clinical pulmonary embolism <1% Iliofemoral DVT VTE Toolkit

  5. Standard therapy: LMWH or IV heparin overlapping with warfarin Follow-up x 24 mos. Symptomatic iliofemoral DVT Catheter-DirectedThrombolysis in Acute DVT (ATTRACT) R • Standard therapy + pharmaco-mechanical CDT: • Trellis-8 • AngioJetRheolytic system • Intra-thrombus rt-PA infusion N=700 30-50 centers NIH-funded S. Vedantham • Primary efficacy outcome: incidence of PTS at 24 mos (Villalta scale) • Secondary efficacy outcomes: severity of PTS; QOL (disease-specific and general); symptoms; valvular reflux & residual thrombus (at 1 year); cost-effectiveness; predictors of response • Safety outcomes: major bleeding, symptomatic PE, rec VTE, death VTE Toolkit

  6. Standard therapy: IV heparin > 48 h  LMWH overlapping with warfarin Follow-up x 1 mo. Thrombolysis in Acute PE (PEITHO) Submassive PE* N~1,000 2007-2010 G. Meyer R Standard therapy + IV bolus tenecteplase *RV dysfunction on echo or CTPA + elevtroponin but normal BP • Primary outcome:composite of all-cause mortality + hemodynamic collapse (CPR, sBP <90 >15 min) within 7 days • Secondary outcomes:death, hemodynamic collapse, recurrent symptomatic PE, stroke, major bleeding within 7days; death <30 days • Sponsors: Assistance Publique – Hopitaux de Paris, German Ministry of Education & Research, Boehringer-Ingelheim VTE Toolkit

  7. Venous Disease Coalition www.vasculardisease.org/venousdiseasecoalition/ VTE Toolkit

More Related